MX2015006955A - Molecular diagnostic test for cancer. - Google Patents

Molecular diagnostic test for cancer.

Info

Publication number
MX2015006955A
MX2015006955A MX2015006955A MX2015006955A MX2015006955A MX 2015006955 A MX2015006955 A MX 2015006955A MX 2015006955 A MX2015006955 A MX 2015006955A MX 2015006955 A MX2015006955 A MX 2015006955A MX 2015006955 A MX2015006955 A MX 2015006955A
Authority
MX
Mexico
Prior art keywords
cancer
angiogenesis
present
test
molecular diagnostic
Prior art date
Application number
MX2015006955A
Other languages
Spanish (es)
Inventor
Andreas Winter
Dennis Paul Harkin
Fionnuala Patterson
Claire Trinder
Eamonn J O'brien
Caroline Michie
Charlie Gourley
Laura A Hill
Katherine E Keating
Jude O'donnell
Steve Deharo
Vitali Proutski
Richard Kennedy
Timothy Davison
Andrena Mccavigan
Max Bylesjo
Original Assignee
Almac Diagnostics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Diagnostics Ltd filed Critical Almac Diagnostics Ltd
Publication of MX2015006955A publication Critical patent/MX2015006955A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30—Unsupervised data analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test identifies cancer subtypes that have an up-regulation or a down- regulation in biomarker expression related to angiogenesis and vascular development. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any anti- angiogenic agent. This test may be used in different cancer types and with different drugs that directly or indirectly affect angiogenesis or angiogenesis signalling. In addition, the present invention may be used as a prognostic indicator for certain cancer types. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.
MX2015006955A 2012-12-03 2013-12-03 Molecular diagnostic test for cancer. MX2015006955A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261732761P 2012-12-03 2012-12-03
PCT/GB2013/053202 WO2014087156A1 (en) 2012-12-03 2013-12-03 Molecular diagnostic test for cancer

Publications (1)

Publication Number Publication Date
MX2015006955A true MX2015006955A (en) 2016-01-25

Family

ID=49780086

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006955A MX2015006955A (en) 2012-12-03 2013-12-03 Molecular diagnostic test for cancer.

Country Status (12)

Country Link
US (1) US11091809B2 (en)
EP (1) EP2925885B1 (en)
JP (1) JP2015536667A (en)
KR (1) KR20150090246A (en)
CN (1) CN105102631A (en)
AU (1) AU2013353839A1 (en)
CA (1) CA2893033A1 (en)
HK (1) HK1214633A1 (en)
IL (1) IL239196A0 (en)
MX (1) MX2015006955A (en)
SG (1) SG11201504023SA (en)
WO (1) WO2014087156A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG195208A1 (en) 2011-06-02 2013-12-30 Almac Diagnostics Ltd Molecular diagnostic test for cancer
AU2013353839A1 (en) 2012-12-03 2015-06-18 Almac Diagnostics Limited Molecular diagnostic test for cancer
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
GB201409479D0 (en) * 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
GB201409476D0 (en) * 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular subtype for use in prognosis
GB201409478D0 (en) * 2014-05-28 2014-07-09 Almac Diagnostics Ltd Pro-angiogenic signature
WO2016011052A1 (en) * 2014-07-14 2016-01-21 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
CN104212440B (en) * 2014-09-03 2016-03-30 无锡艾德美特生物科技有限公司 One class quinazoline ditosylate salt fluorescent probe and Synthesis and applications thereof
CN107109491A (en) * 2014-12-23 2017-08-29 豪夫迈·罗氏有限公司 Composition and method for treating and diagnosing chemotherapy resistant cancer
ES2908848T3 (en) * 2016-01-25 2022-05-04 Sanofi Sa Method of predicting the outcome of aflibercept treatment in a patient suspected of having cancer by measuring the level of a plasma biomarker
CN109154027A (en) * 2016-04-15 2019-01-04 豪夫迈·罗氏有限公司 For monitoring and the method for the treatment of cancer
KR20190007026A (en) * 2016-05-17 2019-01-21 제넨테크, 인크. Substrate Gene Properties for Diagnosis and Use in Immunotherapy
JP6899848B2 (en) 2016-12-28 2021-07-07 公益財団法人がん研究会 Biomarkers, test methods, and test kits for predicting the therapeutic effect of anti-VEGFR-2 antibody drugs
EP3589754B1 (en) 2017-03-01 2023-06-28 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for cancer
US20180358125A1 (en) * 2017-06-13 2018-12-13 Alexander Bagaev Systems and methods for identifying cancer treatments from normalized biomarker scores
EP3652663A4 (en) * 2017-07-14 2021-04-21 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
US10636512B2 (en) * 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
CN107621545B (en) * 2017-07-26 2019-10-11 东南大学 The new application that BICC1 albumen diagnoses mental disease
WO2019074920A1 (en) * 2017-10-10 2019-04-18 Oncocyte Corporation Methods and compositions for detection and diagnosis of breast cancer
DE112018006190T5 (en) * 2017-12-04 2020-08-20 Nantomics, Llc SUBTYPING OF TNBC AND METHODS
CN108524937B (en) * 2018-05-11 2020-05-05 中南大学湘雅三医院 Application of MRVI1-AS1 AS target site in preparation of drugs for treating nasopharyngeal carcinoma paclitaxel chemotherapy sensitization
KR102636164B1 (en) * 2018-08-31 2024-02-13 세노 메디컬 인스투르먼츠 인코포레이티드 Method and system for determining cancer molecular subtypes based on ultrasound and/or photoacoustic characteristics
CN109585011A (en) * 2018-10-26 2019-04-05 朱海燕 The Illnesses Diagnoses method and machine readable storage medium of chest pain patients
CN110358827A (en) * 2019-07-09 2019-10-22 中国人民解放军第四军医大学 The preparation of application and its kit of the VMP1 gene in pathological diagnosis glioblastoma
WO2021034091A1 (en) * 2019-08-19 2021-02-25 재단법인 아산사회복지재단 Method for diagnosing glioblastoma
CN111105843B (en) * 2019-12-31 2023-07-21 杭州纽安津生物科技有限公司 HLAI type molecule and polypeptide affinity prediction method
CN111735949B (en) * 2020-07-17 2023-07-21 北京信诺卫康科技有限公司 Wnt7a and CA125 combined as early ovarian cancer biomarker and kit
CN112266961B (en) * 2020-10-29 2023-05-12 中山大学附属第六医院 Application of TSG-6 gene in predicting colorectal cancer metastasis and prognosis
CN112592397B (en) * 2020-12-31 2022-08-30 上海市胸科医院 CCDC 80-derived polypeptide and application thereof
CN113035298B (en) * 2021-04-02 2023-06-20 南京信息工程大学 Drug clinical trial design method for recursively generating large-order line limiting coverage array
KR20220141216A (en) * 2021-04-12 2022-10-19 연세대학교 산학협력단 A Novel Biomarker for Diagnosing Breast Cancer
WO2022241264A2 (en) * 2021-05-13 2022-11-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Method of targeted multi-panel approach and tiered a.i. use for differential diagnosis and prognosis
CN116482367A (en) * 2023-05-04 2023-07-25 中国中医科学院望京医院(中国中医科学院骨伤科研究所) Colorectal cancer detection method combining mSEPT9 detection and biomarker
CN116519954B (en) * 2023-06-28 2023-10-27 杭州广科安德生物科技有限公司 Colorectal cancer detection model construction method, colorectal cancer detection model construction system and biomarker
CN117089621A (en) * 2023-09-28 2023-11-21 上海爱谱蒂康生物科技有限公司 Biomarker combinations and their use in predicting colorectal cancer efficacy

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
EP0430881A3 (en) 1989-11-29 1991-10-23 Ciba-Geigy Ag Photochromic compounds, process for their preparation and their use
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
JP2775346B2 (en) 1992-04-03 1998-07-16 アプライド バイオシステムズ，インコーポレイテッド Probe composition and method
US5503980A (en) 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5470710A (en) 1993-10-22 1995-11-28 University Of Utah Automated hybridization/imaging device for fluorescent multiplex DNA sequencing
GB9401833D0 (en) 1994-02-01 1994-03-30 Isis Innovation Method for discovering ligands
US6946442B2 (en) 1994-11-30 2005-09-20 Asif Syed Ahmed Method of hastening cervical ripening
GB9507238D0 (en) 1995-04-07 1995-05-31 Isis Innovation Detecting dna sequence variations
US5661028A (en) 1995-09-29 1997-08-26 Lockheed Martin Energy Systems, Inc. Large scale DNA microsequencing device
JP2002515738A (en) 1996-01-23 2002-05-28 アフィメトリックス，インコーポレイティド Nucleic acid analysis
US6680175B2 (en) 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
US6998234B2 (en) 2000-11-03 2006-02-14 Oncotech, Inc. Methods for cancer prognosis and diagnosis relating to tumor vascular endothelial cells
AU2003234613A1 (en) 2002-05-15 2003-12-02 Seul, Kyung, Hwan Method of modulating angiogenesis
AU2003281325A1 (en) 2002-07-02 2004-01-23 The Johns Hopkins University Secreted and cytoplasmic tumor endothelial markers
KR20160114727A (en) 2003-05-30 2016-10-05 제넨테크, 인크. Treatment with anti-VEGF antibodies
US7659062B2 (en) 2003-06-03 2010-02-09 The Board of Trustee of the University of Arkansas System Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
CN102321584B (en) 2003-12-31 2014-01-08 宾夕法尼亚州研究基金会 Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence
US20080113874A1 (en) 2004-01-23 2008-05-15 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
US7871769B2 (en) 2004-04-09 2011-01-18 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
CA2564396A1 (en) * 2004-04-26 2005-11-03 Children's Medical Center Corporation Platelet biomarkers for the detection of disease
JP2007536920A (en) 2004-05-14 2007-12-20 ラドウィッグ・インスティテュート・フォー・キャンサー・リサーチ Identification and characterization of a subpopulation of glioblastoma susceptible to treatment with imatinib
MX2007000944A (en) 2004-07-23 2007-04-13 Astrazeneca Ab Method of predicting the responsiveness oa a tumor to erbb receptor drugs.
JP2008518610A (en) 2004-11-03 2008-06-05 アルマック ダイアグノスティックス リミテッド Transcriptome microarray technique and method of using the same
US7862995B2 (en) * 2004-12-10 2011-01-04 Targeted Molecular Diagnostics Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
ATE477495T1 (en) 2005-03-16 2010-08-15 Osi Pharm Inc BIOLOGICAL MARKERS PREDICTIVE OF CANCER RESPONSIVENESS TO EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITORS
US20080305962A1 (en) 2005-07-29 2008-12-11 Ralph Markus Wirtz Methods and Kits for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapies
WO2007035744A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
EP1963862A4 (en) 2005-12-05 2010-03-03 Merck & Co Inc Methods for predicting treatment response based on the expression profiles of protein and transcription biomakers
WO2007067500A2 (en) 2005-12-05 2007-06-14 Genomic Health, Inc. Predictors of patient response to treatment with egfr inhibitors
US20070212721A1 (en) 2006-01-27 2007-09-13 Tripath Imaging, Inc. Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor
EP2010916A2 (en) 2006-04-13 2009-01-07 Oncomethylome Sciences SA Novel tumour suppressor
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
MX2009002936A (en) 2006-09-19 2009-04-01 Novartis Ag Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors.
US20090082218A1 (en) 2007-08-13 2009-03-26 Paul Harkin 3'-Based sequencing approach for microarray manufacture
WO2009042814A1 (en) 2007-09-25 2009-04-02 Minerva Biotechnologies Corp. Early diagnosis and treatment of drug resistance in muc1-positive cancer
NZ562237A (en) 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
MX2010005057A (en) * 2007-11-09 2010-05-19 Genentech Inc Methods and compositions for diagnostic use in cancer patients.
WO2009076229A2 (en) 2007-12-07 2009-06-18 Oregon Health & Science University Methods to determine if a subject will respond to a bcr-abl inhibitor
WO2009097325A1 (en) * 2008-01-28 2009-08-06 Medimmune Limited Stabilized angiopoietin-2 antibodies and uses thereof
US8114593B2 (en) 2008-03-12 2012-02-14 University Of Medicine And Dentistry Of New Jersey Cancer biomarker genes and gene products and methods for using the same
WO2009149297A1 (en) 2008-06-04 2009-12-10 The Arizona Board Regents, On Behalf Of The University Of Arizona Diffuse large b-cell lymphoma markers and uses therefor
US20110195064A1 (en) 2008-06-06 2011-08-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Survival predictor for diffuse large b cell lymphoma
CN102159727A (en) 2008-07-16 2011-08-17 达纳-法伯癌症研究院有限公司 Signatures and pcdeterminants associated with prostate cancer and methods of use thereof
JP5606438B2 (en) 2008-07-23 2014-10-15 エフ．ホフマン−ラ ロシュ アーゲー Identification of subjects who can receive anti-angiogenic therapy
JP5680547B2 (en) 2008-12-23 2015-03-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Biomarkers for inhibitors with anti-angiogenic activity
WO2010088688A2 (en) 2009-02-02 2010-08-05 Biotheranostics, Inc. Diagnosis of in situ and invasive breast cancer
NZ596054A (en) * 2009-05-01 2013-07-26 Genomic Health Inc Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
US7615353B1 (en) * 2009-07-06 2009-11-10 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
ES2530732T3 (en) * 2009-09-17 2015-03-05 Hoffmann La Roche Diagnostic procedures for lung cancer
EP2975399B1 (en) * 2010-09-15 2022-05-11 Almac Diagnostic Services Limited Molecular diagnostic test for cancer
US20130261018A1 (en) * 2010-10-20 2013-10-03 University Of Tennessee Research Foundation Interferon gene signature and methods of use thereof
WO2012052757A1 (en) 2010-10-20 2012-04-26 Astrazeneca Ab Tumour phenotype patient selection method
CA2823348A1 (en) 2010-12-28 2012-07-05 Caris Mpi, Inc. Molecular profiling for cancer
SG195208A1 (en) 2011-06-02 2013-12-30 Almac Diagnostics Ltd Molecular diagnostic test for cancer
CA2862835A1 (en) 2012-01-13 2013-07-18 Genentech, Inc. Biological markers for identifying patients for treatment with vegf antagonists
EP2667193A1 (en) 2012-05-23 2013-11-27 Université d'Aix-Marseille MMP2 as a predictive biomarker of response to antiangiogenic therapy and survival after therapy in cancer patients
AU2013353839A1 (en) 2012-12-03 2015-06-18 Almac Diagnostics Limited Molecular diagnostic test for cancer

Also Published As

Publication number Publication date
US20160002732A1 (en) 2016-01-07
AU2013353839A1 (en) 2015-06-18
WO2014087156A1 (en) 2014-06-12
US11091809B2 (en) 2021-08-17
HK1214633A1 (en) 2016-07-29
SG11201504023SA (en) 2015-06-29
CN105102631A (en) 2015-11-25
IL239196A0 (en) 2015-07-30
CA2893033A1 (en) 2014-06-12
EP2925885B1 (en) 2020-02-05
JP2015536667A (en) 2015-12-24
KR20150090246A (en) 2015-08-05
EP2925885A1 (en) 2015-10-07

Similar Documents

Publication Publication Date Title
MX2015006955A (en) Molecular diagnostic test for cancer.
SG195208A1 (en) Molecular diagnostic test for cancer
MY166040A (en) Molecular diagnostic test for cancer
MX2016003016A (en) Molecular diagnostic test for lung cancer.
MX356802B (en) Biological markers for identifying patients for treatment with vegf antagonists.
MX2016003077A (en) Molecular diagnostic test for oesophageal cancer.
BR112016004305A2 (en) diagnostic methods and compositions for treating glioblastoma
BR112013006683A2 (en) breast cancer diagnosis
BR112014024219A8 (en) METHODS FOR DETERMINING, OPTIMIZING THERAPEUTIC EFFECTIVENESS, MONITORING, THERAPY SELECTION AND DISORDER DIAGNOSIS AND KIT
BR112012017084A2 (en) methods for predicting triple-negative breast cancer response to therapy
BR112017007962A2 (en) method implemented by computer, device, storage media, computer program, kit, and kit use
ECSP13012461A (en) BIOMARKER TESTS TO DETECT OR MEASURE INHIBITION OF ACTIVITY QUINASA TOR
BR112015001898A2 (en) system for identifying movement artifacts; and method for identifying movement artifacts
BR112016021383A2 (en) METHOD TO IDENTIFY A PATIENT WITH CANCER WHO IS LIKE OR LESS LIKELY TO RESPOND TO TREATMENT WITH A CMET ANTAGONIST, METHOD TO IDENTIFY A PATIENT WITH PREVIOUSLY TREATED CANCER, METHOD TO DETERMINE THE EXPRESSION OF THE HGF BIOMARKER, ANTI-C-MET ANTAGONIST AND ITS USE, DIAGNOSTIC KIT AND ITS PREPARATION METHOD
MX2012001716A (en) Biological markers for monitoring patient response to vegf antagonists.
BR112015020078A8 (en) method for enhancing a gaming experience and physical activity monitoring device
BR112017018008A2 (en) - cancer prognosis and / or diagnosis methods, for determining the dosage of a product, for adjusting the dosage of a product, for determining the beneficial and / or adverse effects of a substance, for identifying a patient as responding to a treatment, to identify a patient as unresponsive to treatment, to treat cancer, means to predict and / or diagnose, kit, use of means and device for cancer identification?
WO2014036387A3 (en) Methods for diagnosis and treatment of cancer
AR088083A1 (en) USE OF ANION BODIES TO IL-1b
PH12015500252A1 (en) Niclosamide for the treatment of solid tumors
BR112015003046A2 (en) neurofeedback system, signal processor for determining a signal characteristic of the measured biofeedback signal, method for providing a user with the neurofeedback and computer program.
WO2013025952A3 (en) Methods and compositions for the treatment and diagnosis of breast cancer
BR112018006339A2 (en) method for assessing the normality of the immune repertoire and its use
EP3495502A3 (en) Biomarkers for premature birth
AR089067A1 (en) BIOMARKERS IN THE SANGUINEO PLASMA FOR BEVACIZUMAB COMBINATION THERAPIES FOR THE TREATMENT OF CANCER DE MAMA